CRUK Beatson Institute, Glasgow, Great Britain.
MRC-University of Glasgow Centre for Virus Research, Glasgow, Great Britain.
Sci Immunol. 2023 Jul 21;8(85):eadg8249. doi: 10.1126/sciimmunol.adg8249.
T cell responses against infections and cancer are directed by conventional dendritic cells (cDCs) in lymph nodes distant from the site of challenge. Migratory cDCs, which travel from the tissue to the lymph node, not only drive initial T cell activation but also transfer antigen to lymph node-resident cDCs. These resident cells have essential roles defining the character of the resulting T cell response; however, it is unknown how they can appropriately process and present antigens to suitably direct responses given their spatial separation. Here, using a novel strain of influenza A and a modified melanoma model, we show that tissue and lymph node cDC activation is harmonized and that this is driven by cotransfer of contextual cues. In the tumor, incomplete cDC activation in the tumor microenvironment is mirrored by lymph node-resident cDCs, whereas during influenza infection, pathogen-associated molecular patterns cotransferred with antigen drive TLR signaling in resident cDCs and their subsequent robust activation. This cotransfer mechanism explains how individual antigens can be handled distinctly by resident cDCs and how signals driving poor tumoral cDC activation further impact the lymph node. Our findings clarify how tissue context dictates antigenic and, consequently, T cell fate in the lymph node.
T 细胞对感染和癌症的反应是由淋巴结中远离挑战部位的常规树突状细胞(cDC)指导的。从组织迁移到淋巴结的迁移性 cDC 不仅驱动初始 T 细胞激活,还将抗原转移到淋巴结驻留的 cDC。这些常驻细胞在定义产生的 T 细胞反应特征方面具有重要作用;然而,尚不清楚它们如何能够在空间分离的情况下适当处理和呈递抗原,以适当地指导反应。在这里,我们使用新型流感 A 株和改良的黑色素瘤模型,表明组织和淋巴结 cDC 的激活是协调的,这是由上下文线索的共转移驱动的。在肿瘤中,肿瘤微环境中不完全的 cDC 激活在淋巴结驻留的 cDC 中得到反映,而在流感感染期间,与抗原共转移的病原体相关分子模式驱动 TLR 信号在驻留的 cDC 中,并随后使其强烈激活。这种共转移机制解释了单个抗原如何被驻留的 cDC 以不同的方式处理,以及驱动肿瘤 cDC 激活不良的信号如何进一步影响淋巴结。我们的研究结果阐明了组织环境如何决定淋巴结中的抗原性和随后的 T 细胞命运。
Life Sci Alliance. 2022-9
Cancer Med. 2025-9
Nat Commun. 2025-1-30
Mol Cancer. 2024-9-9
Eur Respir Rev. 2024-4-30
Annu Rev Immunol. 2021-4-26
Cancer Cell. 2020-6-8
Nat Rev Mol Cell Biol. 2020-5-26
J Immunother Cancer. 2019-5-2